[Evaluation of the effects of a beta-blocking drug (moprolol) on hemodynamics and lesion potentials in acute myocardial infarct].

L. De Ambroggi,G. Perotta,R. Satolli,A. Lotto

Abstract:

What problem does this paper attempt to address?

Bruceine D suppresses CAF-promoted TNBC metastasis under TNF-α stimulation by inhibiting Notch1-Jagged1/NF-κB(p65) signaling

Han Chen,Xue Han,Yue Zhang,Ke Wang,Da Liu,Zhiqiang Hu,Jing Wang

DOI: https://doi.org/10.1016/j.phymed.2023.154928

IF: 6.656

Phytomedicine

Abstract:Background: Triple-negative breast cancer (TNBC) has a poor prognosis because of its high degree of malignancy and the lack of effective treatment options. Cancer-associated fibroblasts (CAFs) comprise the most abundant stromal cells in the tumor microenvironment (TME), leading to functional impairments and facilitating tumor metastasis. Excessive TNF-α further promotes cross-talk between different cells in TME. Therefore, there is an urgent need to develop more effective therapies and potential drugs that target the key factors that promote TNBC metastasis. Purpose: The study aimed to evaluate the efficacy of Bruceine D, an active compound derived from the Chinese herb Brucea javanica, in inhibiting metastasis and elucidate the underlying mechanism of action in TNBC. Methods: In vitro, the clonogenic and the Transwell assays were used to assess the effects of Bruceine D on the proliferation, migration and invasion abilities of co-cultured CAFs and MDA-MB-231 (4T1) cells under TNF-α stimulation. TNF-α, IL-6, CXCL12, TGF-β1, and MMP9 levels in the supernatant of co-cultured cells were determined using ELISA. Western blotting was utilized to detect the expression levels of proteins related to the Notch1-Jagged1/NF-κB(p65) pathway. In vivo, the anti-tumor growth and anti-metastatic effectiveness of Bruceine D was evaluated by determining tumor weight, number of metastatic lesions, and pathological changes in the tumor and lung/liver tissues. The inhibitory effect of Bruceine D on α-SMA+ CAFs activation and CAF-medicated extracellular matrix remodeling was accessed using immunohistochemistry, immunofluorescence, and Masson and Sirius Red staining. The expression levels of Notch1, Jagged1 and p-NF-κB(p65) proteins in the primary tumors were measured by immunohistochemistry and western blotting. Results: In vitro, Bruceine D significantly inhibited the migration and invasion of co-cultured CAFs and MDA-MB-231 (4T1) cells under TNF-α stimulation, reduced the expression of tumor-promoting and matrix-remodeling cytokines secreted by CAFs, and hindered the mutual activation of Notch1-Jagged1 and NF-κB(p65). In vivo, Bruceine D significantly suppressed tumor growth and the formation of lung and liver metastases by decreasing TNF-α stimulated α-SMA+ CAFs activation, collagen fibers, MMPs production, and inhibited Notch1-Jagged1/NF-κB(p65) signaling in TNBC-bearing mice. Conclusion: Bruceine D effectively weakened the "tumor-CAF-inflammation" network by inhibiting the mutual activation of Notch1-Jagged1 and NF-κB(p65) and thereby suppressed TNBC metastasis. This study first explored that Bruceine D disrupted the cross-talk between CAFs and tumor cells under TNF-α stimulation to inhibit the metastasis of TNBC, and highlighted the potential of Bruceine D as therapeutic agent for suppressing tumor metastasis.
Bruceine D Induces Apoptosis in Human Non-Small Cell Lung Cancer Cells Through Regulating JNK Pathway

Biqin Tan,Yuyu Huang,Lihua Lan,Bo Zhang,Lijun Ye,Wei Yan,Fei Wang,Nengming Lin

DOI: https://doi.org/10.1016/j.biopha.2019.109089

IF: 7.419

2019-01-01

Biomedicine & Pharmacotherapy

Abstract:Bruceine D (BD) is the quassinoids isolated from the traditional Chinese herbal medicine Brucea javanica's fruit, which exhibits anti-cancer activity. Here, we demonstrated that BD inhibited human non-small cell lung cancer (NSCLC) cell lines in vitro that were attributed to the induction of cell apoptosis. Human NSCLC H460 and A549 cell lines were treated with BD, and cell viability was conducted with CCK-8 assay. Cell clone formation was observed by clone formation assay. Cell apoptosis was measured using DAPI staining and flow cytometry. Protein levels was analyzed by western blot. The results showed BD inhibited the cell viability of H460 and A549 cells in a dose-dependent manner with IC50 values of 0.5 and 0.6 mu mol/L, respectively, at 48 h of treatment. Treatment with BD (0.125-1.0 mu mol/L) dose-dependently promoted chromatin condensation, Annexin V-positive cell population and caspase-dependent apoptosis in H460 and A549 cells. Mechanistically, BD stimulated the phosphorylation of JNK. Furthermore, the anti-cancer effects of BD were alleviated effectively by a specific JNK inhibitor SP600125 in NSCLC cells. In conclusion, the results demonstrated that BD exerted anti-cancer activity against NSCLC cells through JNK activation, which suggests its potent usefulness for prevention and treatment of NSCLC.
Bruceine a exerts antitumor effect against colon cancer by accumulating ROS and suppressing PI3K/Akt pathway

Chaozheng Zhang,Yuening Cao,Yi Zuo,Hongbin Cheng,Changqun Liu,Xila Xia,Bo Ren,Yun Deng,Maolin Wang,Jun Lu

DOI: https://doi.org/10.3389/fphar.2023.1149478

IF: 5.6

2023-03-29

Frontiers in Pharmacology

Abstract:Bruceine A (BA), a quassic ester from bruceine javanica , regulates diverse intracellular signal transduction pathways and manifests a variety of biological activities, however, its pharmacological mechanism in treating colon cancer (CC) is unclear. In this study, we investigated the anticancer effects of BA on CC cells and the underlying mechanisms. The network pharmacology research indicated that Akt1 and Jun and PI3K/Akt pathways are the predominant targets and critical signaling pathways, respectively, for BA treatment of CC. Meanwhile, molecular docking results implied that BA could conjugate to pivotal proteins in the PI3K/Akt pathway. BA remarkably suppressed the proliferation of CC cells HCT116 and CT26 with 48-h IC50 of 26.12 and 229.26 nM, respectively, and the expression of p-PI3K/p-Akt was restrained by BA at the molecular level as verified by Western blot assay. Further mechanistic studies revealed BA impacted cell cycle-related proteins by regulating the expression of P27 (a protein bridging the PI3K/Akt signaling pathway with cycle-related proteins), arresting the cell cycle in the G2 phase, inhibiting the proliferation of HCT116 and CT26, and facilitated the apoptosis in CC cells by activating the mitochondria-associated apoptosis protein Bax and accumulating reactive oxygen species, in addition to BA apparently inhibited the migration of CC cells. Taken together, our results demonstrated that BA might be a promising chemotherapy drug in the treatment of CC.

pharmacology & pharmacy
Betulinic acid impairs metastasis and reduces immunosuppressive cells in breast cancer models

An-Qi Zeng,Yan Yu,Yu-Qin Yao,Fang-Fang Yang,Mengya Liao,Lin-Jiang Song,Ya-Li Li,Yang Yu,Yu-Jue Li,Yuan-Le Deng,Shu-Ping Yang,Chen-Juan Zeng,Ping Liu,Yong-Mei Xie,Jin-Liang Yang,Yi-Wen Zhang,Ting-Hong Ye,Yu-Quan Wei

DOI: https://doi.org/10.18632/oncotarget.23376

2017-12-17

Oncotarget

Abstract:Breast cancer is the most common female cancer with considerable metastatic potential, explaining the need for new candidates that inhibit tumor metastasis. In our study, betulinic acid (BA), a kind of pentacyclic triterpenoid compound derived from birch trees, was evaluated for its anti-metastasis activity in vitro and in vivo. BA decreased the viability of three breast cancer cell lines and markedly impaired cell migration and invasion. In addition, BA could inhibit the activation of stat3 and FAK which resulted in a reduction of matrix metalloproteinases (MMPs), and increase of the MMPs inhibitor (TIMP-2) expression. Moreover, in our animal experiment, intraperitoneal administration of 10 mg/kg/day BA suppressed 4T1 tumor growth and blocked formation of pulmonary metastases without obvious side effects. Furthermore, histological and immunohistochemical analyses showed a decrease in MMP-9 positive cells, MMP-2 positive cells and Ki-67 positive cells and an increase in cleaved caspase-3 positive cells upon BA administration. Notably, BA reduced the number of myeloid-derived suppressor cells (MDSCs) in the lungs and tumors. Interestingly, in our caudal vein model, BA also obviously suppressed 4T1 tumor pulmonary metastases. These findings suggested that BA might be a potential agent for inhibiting the growth and metastasis of breast cancer.
Unveiling the therapeutic potential: KBU2046 halts triple-negative breast cancer cell migration by constricting TGF-β1 activation in vitro

Jinxia Chen,Suli Dai,Geng Zhang,Sisi Wei,Xuetao Zhao,Yang Zheng,Yaojie Wang,Xiaohan Wang,Yunjiang Liu,Lianmei Zhao

DOI: https://doi.org/10.32604/or.2024.049348

2024-10-16

Abstract:Background: Triple-negative breast cancer (TNBC) is a heterogeneous, recurring cancer characterized by a high rate of metastasis, poor prognosis, and lack of efficient therapies. KBU2046, a small molecule inhibitor, can inhibit cell motility in malignant tumors, including breast cancer. However, the specific targets and the corresponding mechanism of its function remain unclear. Methods: In this study, we employed (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H tetrazolium) (MTS) assay and transwell assay to investigate the impact of KBU2046 on the proliferation and migration of TNBC cells in vitro. RNA-Seq was used to explore the targets of KBU2046 that inhibit the motility of TNBC. Finally, confirmed the predicted important signaling pathways through RT-qPCR and western blotting. Results: In this study, we found that KBU2046 functioned as a novel transforming growth factor-β (TGF-β1) inhibitor, effectively suppressing tumor cell motility in vitro. Mechanistically, it directly down-regulated leucine-rich repeat-containing 8 family, member E (LRRC8E), latent TGFβ-binding protein 3 (LTBP3), dynein light chain 1 (DNAL1), and MAF family of bZIP transcription factors (MAFF) genes, along with reduced protein expression of the integrin family. Additionally, KBU2046 decreased phosphorylation levels of Raf and ERK. This deactivation of the ERK signaling pathway impeded cancer invasion and metastasis. Conclusions: In summary, these findings advocate for the utilization of TGF-β1 as a diagnostic and prognostic biomarker and as a therapeutic target in TNBC. Furthermore, our data underscore the potential of KBU2046 as a novel therapeutic strategy for combating cancer metastasis.
Bruceine B Displays Potent Antimyeloma Activity by Inducing the Degradation of the Transcription Factor C-Maf.

Hongyue Li,Xiaoting Zhu,Ziying Sun,Qi Wang,Shaojiang Song,Yujia Xu,Guisong He,Xinliang Mao

DOI: https://doi.org/10.1021/acsptsci.3c00222

2023-01-01

Abstract:The oncogenic transcription factor c-Maf has been proposed as an ideal therapeutic target for multiple myeloma (MM), a not-yet-curable malignancy of plasma cells. In the present study, we establish a c-Maf-based luciferase screen system and apply it to screen a homemade library composed of natural products from which bruceine B (BB) is identified to display potent antimyeloma activity. BB is a key ingredient isolated from the Chinese traditional medicinal plant Brucea javanica (L.) Merr. (Simaroubaceae). BB inhibits MM cell proliferation and induces MM cell apoptosis in a caspase-3-dependent manner. The mechanism studies showed that BB inhibits c-Maf transcriptional activity and downregulates the expression of CCND2 and ITGB7, the downstream genes typically modulated by c-Maf. Moreover, BB induces c-Maf degradation via proteasomes by inducing c-Maf for K48-linked polyubiquitination in association with downregulated Otub1 and USP5, two proven deubiquitinases of c-Maf. We also found that c-Maf activates STAT3 and BB suppresses the STAT3 signaling. In the in vivo study, BB displays potent antimyeloma activity and almost suppresses the growth of myeloma xenografts in 7 days but shows no overt toxicity to mice. In conclusion, this study identifies BB as a novel inhibitor of c-Maf by promoting its degradation via the ubiquitin-proteasomal pathway. Given the safety and the successful clinical application of bruceine products in traditional medicine, BB is ensured for further investigation for the treatment of patients with MM.
Proliferation, migration and invasion of triple negative breast cancer cells are suppressed by berbamine via the PI3K/Akt/MDM2/p53 and PI3K/Akt/mTOR signaling pathways

Lili Liu,Jiadong Yan,Ying Cao,Yan Yan,Xiang Shen,Binbin Yu,Li Tao,Shusheng Wang

DOI: https://doi.org/10.3892/ol.2020.12331

2020-11-25

Oncology Letters

Abstract:Breast cancer is the second most common cause of cancer-associated mortality among women worldwide, and triple negative breast cancer (TNBC) is the most aggressive subtype of breast cancer. Berbamine (BBM) is a traditional Chinese medicine used for the treatment of leukopenia without any obvious side effects. Recent reports found that BBM has anti-cancer effects. The present study aimed to investigate the effects of BBM on TNBC cell lines and the underlying molecular mechanism. MDA-MB-231 cells and MCF-7 cells, two TNBC cell lines, were treated with various concentrations of BBM. A series of bioassays including MTT, colony formation, EdU staining, apoptosis, trypan blue dye, wound healing, transwell, ELISA and western blotting assays were performed. The results showed that BBM significantly inhibited cell proliferation of MDA-MB-231 cells (P<0.05; IC50=22.72 µM) and MCF-7 cells (P<0.05; IC50=20.92 µM). BBM (20 µM) decreased the apoptosis ratio (percentage of absorbance compared with the control group) by 28.4±3.3% (P<0.05) in MDA-MB-231 cells, and 62.4±24.6% (P<0.05) in MCF-7 cells. In addition, BBM inhibited cell migration and invasion of TNBC cells. Furthermore, the expression levels of PI3K, phosphorylated-Akt/Akt, COX-2, LOX, MDM2 and mTOR were downregulated by BBM, and the expression of p53 was upregulated by BBM. These results indicated that BBM may suppress the development of TNBC via regulation of the PI3K/Akt/MDM2/p53 and PI3K/Akt/mTOR signal pathways. Therefore, BBM might be used as a drug candidate for the treatment of TNBC in the future.

oncology
Bruceae Fructus Oil Inhibits Triple-Negative Breast Cancer by Restraining Autophagy: Dependence on the Gut Microbiota-Mediated Amino Acid Regulation

Jiyan Su,Xiaohong Chen,Yuanjie Xiao,Dan Li,Muxia Li,Hongfu Li,Jiangjian Huang,Zhengquan Lai,Ziren Su,Yizhen Xie,Dajiang Zhu,Qianjun Chen,Hai Lu,Jingjin He,Chenglai Xia

DOI: https://doi.org/10.3389/fphar.2021.727082

IF: 5.6

2021-10-01

Frontiers in Pharmacology

Abstract:Triple-negative breast cancer (TNBC) has been acknowledged as an aggressive disease with worst prognosis, which requires endeavor to develop novel therapeutic agents. Bruceae fructus oil (BO), a vegetable oil derived from the fruit of Brucea javanica (L.) Merr., is an approved marketable drug for the treatment of cancer in China for several decades. Despite that the anti–breast cancer activity of several quassinoids derived from B. javanica has been found, it was the first time that the potential of BO against TNBC was revealed. Although BO had no cytotoxicity on TNBC cell lines in vitro , the oral administration of BO exhibited a gut microbiota–dependent tumor suppression without toxicity on the non-targeted organs in vivo . By metagenomics and untargeted metabolomics, it was found that BO not only altered the composition and amino acid metabolism function of gut microbiota but also regulated the host’s amino acid profile, which was in accordance with the metabolism alternation in gut microbiota. Moreover, the activity of mTOR in tumor was promoted by BO treatment as indicated by the phosphorylation of 4E-binding protein 1 (4E-BP1) and ribosomal protein S6, and hyper-autophagy was consequently restrained. By contrast, the failure of tumor suppression by BO under pseudo germ-free (PGF) condition came with indistinctive changes in autophagy and mTOR activity, implying the critical role of the gut microbiota in BO’s anticancer activity. The present study highlighted a promising application of BO against breast cancer with novel efficacy and safety.

pharmacology & pharmacy
Bruceine D induces lung cancer cell apoptosis and autophagy via the ROS/MAPK signaling pathway in vitro and in vivo

Jiangjiang Fan,Dongmei Ren,Jinxia Wang,Xiaoqing Liu,Huaran Zhang,Mingsheng Wu,Guotao Yang

DOI: https://doi.org/10.1038/s41419-020-2317-3

2020-02-01

Cell Death and Disease

Abstract:Abstract Worldwide, lung cancer remains a leading cause of cancer mortality. Bruceine D (BD) has been shown to induce pancreatic cancer cell death via several different mechanisms. In this study, we demonstrated that BD inhibited lung cancer cell proliferation. Apoptosis and autophagy were the most important mechanisms involved in BD-induced lung cancer cell death, and complete autophagic flux was observed in A549 and NCI-H292 cells. In addition, BD significantly improved intracellular reactive oxygen species (ROS) levels. BD-mediated cell apoptosis and autophagy were almost inhibited in cells pretreated with N-acetylcysteine (NAC), an ROS scavenger. Furthermore, MAPK signaling pathway activation contributed to BD-induced cell proliferation inhibition and NAC could eliminate p-ERK and p-JNK upregulation. Finally, an in vivo study indicated that BD inhibited the growth of lung cancer xenografts. Overall, BD is a promising candidate for the treatment of lung cancer owing to its multiple mechanisms and low toxicity.

cell biology
Viable Aortic Valve Heterotransplantation

H. Mohri,D. Reichenbach,R. Barnes,G. Pierce,Ingegerd E. Hellström,K. Merendino

DOI: https://doi.org/10.1161/01.CIR.39.5S1.I-31

IF: 37.8

1969-05-01

Circulation

Abstract:THE SUPERIOR hemodynamic and antithrombogenic characteristics of biological aortic valves over prosthetic valves have stimulated the use of homologous or heterologous aortic valves.l1 These grafts appear to function satisfactorily, although heterografts have been followed for only two years. The long-term fate of transplanted heterologous valves may be expected to be nearly the same as that of homografts, since sterilized dead tissue has been used clinically. However, it is believed that viable heterografts will be rejected and destroyed quickly unless immunosuppressive measures are taken.5 The present studies have been undertaken to evaluate the ultimate fate of these grafts and host-immune reactions, and to determine the applicability of viable heterologous aortic valves.
Betulinic Acid Suppresses Breast Cancer Metastasis by Targeting GRP78-Mediated Glycolysis and ER Stress Apoptotic Pathway

Yifeng Zheng,Pengxi Liu,Neng Wang,Shengqi Wang,Bowen Yang,Min Li,Jianping Chen,Honglin Situ,Meiqi Xie,Yi Lin,Zhiyu Wang

DOI: https://doi.org/10.1155/2019/8781690

2019-08-19

Oxidative Medicine and Cellular Longevity

Abstract:Targeting aberrant metabolism is a promising strategy for inhibiting cancer growth and metastasis. Research is now geared towards investigating the inhibition of glycolysis for anticancer drug development. Betulinic acid (BA) has demonstrated potent anticancer activities in multiple malignancies. However, its regulatory effects on glycolysis and the underlying molecular mechanisms are still unclear. BA inhibited invasion and migration of highly aggressive breast cancer cells. Moreover, BA could suppress aerobic glycolysis of breast cancer cells presenting as a reduction of lactate production, quiescent energy phenotype transition, and downregulation of aerobic glycolysis-related proteins. In this study, glucose-regulated protein 78 (GRP78) was also identified as the molecular target of BA in inhibiting aerobic glycolysis. BA treatment led to GRP78 overexpression, and GRP78 knockdown abrogated the inhibitory effect of BA on glycolysis. Further studies demonstrated that overexpressed GRP78 activated the endoplasmic reticulum (ER) stress sensor PERK. Subsequent phosphorylation of eIF2 α led to the inhibition of β -catenin expression, which resulted in the inhibition of c-Myc-mediated glycolysis. Coimmunoprecipitation assay revealed that BA interrupted the binding between GRP78 and PERK, thereby initiating the glycolysis inhibition cascade. Finally, the lung colonization model validated that BA inhibited breast cancer metastasis in vivo , as well as suppressed the expression of aerobic glycolysis-related proteins. In conclusion, our study not only provided a promising drug for aerobic glycolysis inhibition but also revealed that GRP78 is a novel molecular link between glycolytic metabolism and ER stress during tumor metastasis.

cell biology
Betulinic acid in the treatment of breast cancer: Application and mechanism progress

Huijuan Mu,Yuli Sun,Bo Yuan,Ying Wang

DOI: https://doi.org/10.1016/j.fitote.2023.105617

IF: 3.204

2023-07-21

Fitoterapia

Abstract:Betulinic acid (BA) is a pentacyclic triterpene compound, which can be obtained by separation, chemical synthesis and biotransformation. BA has excellent biological activities, especially its role in the treatment of breast cancer deserves attention. Its mechanisms mainly include inducing mitochondrial oxidative stress, regulating specific protein (Sp) transcription factors, inhibiting breast cancer metastasis, inhibiting glucose metabolism and NF-κB pathway. In addition, BA can also increase the sensitivity of breast cancer cells to other chemotherapy drugs such as paclitaxel and reduce its toxic side effects. This article reviews the application and possible mechanism of BA in the treatment of breast cancer.

pharmacology & pharmacy,chemistry, medicinal
Bruceine D and Narclasine inhibit the proliferation of breast cancer cells and the prediction of potential drug targets

Xinhao Chen,Hua Li

DOI: https://doi.org/10.1371/journal.pone.0297203

IF: 3.7

2024-01-13

PLoS ONE

Abstract:Breast cancer is one of the most common female malignancies. This study explored the underlying mechanism through which the two plant compounds (Brucaine D and Narclasine) inhibited the proliferation of breast cancer cells. The purpose of this study was to explore the effect of Brucaine D and Narclasine on breast cancer development and their potential drug targets. GSE85871 dataset containing 212 samples and the hallmark gene set "h.all.v2023.1.Hs.symbols.gmt" were downloaded from the Gene Expression Omnibus (GEO) database and the Molecular Signatures Database (MSigDB) database, respectively. Principal component analysis (PCA) was applied to classify clusters showing similar gene expression pattern. Single sample gene set enrichment analysis (ssGSEA) was used to calculate the hallmark score for different drug treatment groups. The expressions of genes related to angiogenesis, glycolysis and cell cycle were detected. Protein-protein interaction (PPI) network analysis was performed to study the interaction of the hub genes. Then, HERB database was employed to identify potential target genes for Narclasine and Bruceine D. Finally, in vitro experiments were conducted to validate partial drug-target pair. PCA analysis showed that the significant changes in gene expression patterns took place in 6 drugs treatment groups (Narciclasine, Bruceine D, Japonicone A, 1beta-hydroxyalatolactone, Britanin, and four mixture drugs) in comparison to the remaining drug treatment groups. The ssGSEA pathway enrichment analysis demonstrated that Narciclasine and Bruceine treatments had similar enriched pathways, for instance, suppressed pathways related to angiogenesis, Glycolysis, and cell cycle, etc.. Further gene expression analysis confirmed that Narciclasine and Bruceine had a strong ability to inhibit these cell cycle genes, and that MYC, CHEK2, MELK, CDK4 and EZH2 were closely interacted with each other in the PPI analysis. Drug target prediction revealed that Androgen Receptor (AR) and Estrogen Receptor 1 (ESR1) were the targets for Bruceine D, and Cytochrome P450 3A4 enzyme (CYP3A4) was the target for Narciclasine. Cell experiments also confirmed the connections between Narciclasine and CYP3A4. The present study uncovered that Narciclasine and Bruceine D could inhibit the growth of breast cancer and also predicted the potential targets for these two drugs, providing a new therapeutic direction for breast cancer patients.

multidisciplinary sciences
Transdermal Delivery of Brucine-Encapsulated Liposomes Significantly Enhances Anti-Tumor Outcomes in Treating Triple-Negative Breast Cancer.

Min Wu,Yi Hu,Mengran Xu,Lijuan Fu,Chengpan Li,Jingjing Wu,Xin Sun,Wenshen Wang,Shaozhen Wang,Ting Wang,Weiping Ding,Ping Li

DOI: https://doi.org/10.1016/j.bioadv.2023.213566

2023-01-01

Biomaterials Advances

Abstract:Triple-negative breast cancer (TNBC) is always the most challenging breast cancer subtype. Herein, brucine, encapsulated in peptide-modified liposomes, was proposed for treating TNBC by transdermal delivery. For the TD peptide-modified brucine-loaded liposome (Bru-TD-Lip) we developed, it presents high encapsulation efficiency of brucine and stability. In vitro, Bru-TD-Lip shows the enhanced percutaneous permeability of brucine, is able to readily enter TNBC cells, and significantly inhibits the proliferation, migration, and invasion of these cells. In vivo, through transdermal delivery, Bru-TD-Lip presents good biosafety and anti-tumor efficacy. The transdermal delivery of Bru-TD-Lip effectively targets and inhibits subcutaneous mammary carcinogenesis in female nude mice. Compared with oral administration, the transdermal delivery significantly reduces the damage of brucine to major organs and enhances the antitumor outcomes of brucine in treating TNBC. This study provides a new therapeutic strategy for treating triple-negative breast cancer by brucine.
Betulinic acid inhibits stemness and EMT of pancreatic cancer cells via activation of AMPK signaling

Liankang Sun,Junyu Cao,Ke Chen,Liang Cheng,Cancan Zhou,Bin Yan,Weikun Qian,Jie Li,Wanxing Duan,Jiguang Ma,Dan Qi,Erxi Wu,Zheng Wang,Qingguang Liu,Qingyong Ma,Qinhong Xu

DOI: https://doi.org/10.3892/ijo.2018.4604

Abstract:Cancer stem cells (CSCs), which are found in various types of human cancer, including pancreatic cancer, possess elevated metastatic potential, lead to tumor recurrence and cause chemoradiotherapy resistance. Alterations in cellular bioenergetics through the regulation of 5' adenosine monophosphate‑activated protein kinase (AMPK) signaling may be a prerequisite to stemness. Betulinic acid (BA) is a well‑known bioactive compound with antiretroviral and anti‑inflammatory potential, which has been reported to exert anticancer effects on various types of cancer, including pancreatic cancer. The present study aimed to investigate whether BA could inhibit pancreatic CSCs via regulation of AMPK signaling. The proliferation of pancreatic cancer cells was examined by MTT and colony formation assays. The migratory and invasive abilities of pancreatic cancer cells were assessed using wound‑scratch and Transwell invasion assays. In addition, the expression levels of candidate genes were measured by reverse transcription‑quantitative polymerase chain reaction and western blotting. The results revealed that BA inhibited the proliferation and tumorsphere formation of pancreatic cancer cells, suppressed epithelial‑mesenchymal transition (EMT), migration and invasion, and reduced the expression of three pluripotency factors [SRY‑box 2 (Sox2), octamer‑binding protein 4 (Oct4) and Nanog]. Furthermore, immunohistochemical analysis confirmed that there was a significant inverse association between the expression levels of phosphorylated (P)‑AMPK and Sox2 in pancreatic cancer, and it was revealed that BA may activate AMPK signaling. Notably, knockdown of AMPK reversed the suppressive effects of BA on EMT and stemness of pancreatic cancer cells. In addition, BA reversed the effects of gemcitabine on stemness and enhanced the sensitivity of pancreatic cancer cells to gemcitabine. Collectively, these results indicated that BA may effectively inhibit pluripotency factor expression (Sox2, Oct4 and Nanog), EMT and the stem‑like phenotype of pancreatic cancer cells via activating AMPK signaling. Therefore, BA may be considered an attractive therapeutic candidate and an effective inhibitor of the stem‑like phenotype in pancreatic cancer cells. Further investigation into the development of BA as an anticancer drug is warranted.
Betulinic acid inhibits the proliferation of human laryngeal carcinoma cells through reactive oxygen species-mediate mitochondrial apoptotic pathway

Huamin Zhang,Mengru Zhou,Chongtao Ye,Jiahao Qin,Xuan Lu,Chunyan Wang,Xude Wang,Xuejun Jin

DOI: https://doi.org/10.1016/j.tiv.2023.105756

Abstract:Betulinic acid (BA), a natural pentacyclic triterpene, was extracted from the white birch tree, Triphyophyllum peltatum and the jujube tree. In a variety of human cancer cell lines, this substance displays anticancer properties. In this study, we examined how BA works to inhibit human laryngeal cancer growth. We discovered that BA minimally exhibited cytotoxicity in normal cells (human normal cell line GES-1), while remarkably inhibiting viability of AMC-HN-8, TU212, HEp-2 and M4e cells in a concentration-dependent manner. In AMC-HN-8 cancer cells, BA induced apoptosis, activated caspase-3/9/PARP, significantly reduced mitochondrial membrane potential (MMP), increased the expression of cytochrome C in the cytoplasm, transported Bax to the mitochondria, increased the production of reactive oxygen species (ROS), and the ROS scavenger N-acetylcysteine can reduce apoptosis. All data showed that BA triggered apoptosis via the mitochondrial pathway, in which ROS production was likely involved. The findings support the development of BA as a viable drug for the treatment of human laryngeal carcinoma.
Baicalein promotes KDM4E to induce BICD1 and inhibit triple‐negative breast cancer progression by blocking PAR1 signaling

Yun Dong,Gaojian He,Kun Chen,Xuefeng He,Meitong Pan,Xuemei Huang,Xiaolan Yu,Jiyi Xia

DOI: https://doi.org/10.1002/mc.23724

2024-04-13

Molecular Carcinogenesis

Abstract:Baicalein has been implicated in the chemotherapy overcoming triple‐negative breast cancer (TNBC). However, many unanswered questions remain regarding its role in treating TNBC. Here, we sought to demonstrate the molecular pathway mediated by baicalein in TNBC. Lysine‐specific demethylase 4E (KDM4E), reduced in TNBC cells, was identified as a target protein of baicalein, and baicalein enhanced the protein expression and stability of KDM4E in TNBC cells. Knockdown of KDM4E attenuated the inhibitory effect of baicalein on TNBC cell activity, as demonstrated by intensified mobility, viability, and apoptosis resistance in TNBC cells. KDM4E activated protein bicaudal D homolog 1 (BICD1) expression by reducing the deposition of histone H3 lysine 9 trimethylation (H3K9me3) in its promoter, whereas BICD1 promoted protease‐activated receptor‐1 (PAR1) endocytosis and blocked PAR1 signaling through physical interaction with PAR1. Knockdown of KDM4E strengthened the PAR1‐dependent activity of TNBC cells in response to thrombin activation, whereas TNBC progression activated by PAR1 signaling was blocked by combined overexpression of BICD1. Taken together, our data indicate that baicalein‐promoted KDM4E enhanced the expression of BICD1 and activated the inhibitory effect of BICD1 on PAR1 signaling, thereby inhibiting TNBC progression.

oncology,biochemistry & molecular biology
3-Acetyl-11-keto-β-boswellic acid inhibits cancer cell invasion and induces apoptosis in breast cancer cells by abrogating the EGFR-mediated PI3K/Akt pathway

Ruishan Zhang,Hong Xu,Xiang Li,Zhuangkai Liu,Yuying Wang,Zhao Zhao

DOI: https://doi.org/10.5114/aoms.2020.95421

2020-05-18

Archives of Medical Science

Abstract:Introduction Recent evidence has demonstrated the anticancer potential of 3-acetyl-11-keto-β-boswellic acid (AKBA). The current study was performed to evaluate the anti-invasive and antimotility effect of AKBA against breast cancer (BC) cells. Material and methods The antiproliferative assay was used to evaluate cell viability. Wound healing assay and Transwell invasion assay were used for migration and invasion respectively. Annexin V FITC assay and microscopy were used to quantify and detect apoptosis. Zymography and immunoblotting analysis were used for gelatinase activity of matrix metalloproteinases (MMPs) and protein expression of signaling proteins involved in apoptosis, tumor cell invasion and motility of BC cells. Results AKBA exhibits significant inhibition of cell proliferation and suppresses BC cell motility. Mechanistically, AKBA suppresses migration and invasion, and attenuates MMP-2 and MMP-9 activity, which plays a key role in metastasis. Furthermore, a dose-dependent manner of AKBA promotes significant induction of apoptosis. Moreover, we observed that a higher concentration of AKBA reduces phosphorylation of EGFR, PI3K, and Akt with a subsequent decrease in MMP-9 and MMP-2 expression, and an increase in TIMP1 and E-cadherin expression. However, pre-treatment with EGF in BC cells restores significant cell motility and invasion even in the presence of AKBA, indicating that inhibition of cell migration by AKBA is operated by the EGFR/PI3K/Akt axis. Additionally, AKBA showed a significant inhibitory and strong synergistic effect on EGFR-mediated PI3K/Akt signaling associated proteins when compared with the known inhibitors gefitinib and erlotinib. Conclusions AKBA exhibits potential antiproliferative effects by inducing apoptosis and suppresses tumor cell motility and invasion, which is mediated by the EGFR/PI3K/Akt axis in BC cells.

medicine, general & internal
Combination Treatment With Inhibitors of ERK and Autophagy Enhances Antitumor Activity of Betulinic Acid in Non–small-Cell Lung Cancer In Vivo and In Vitro

Chao-Yue Sun,Di Cao,Qian-Nan Ren,Shan-Shan Zhang,Ning-Ning Zhou,Shi-Juan Mai,Bing Feng,Hui-Yun Wang

DOI: https://doi.org/10.3389/fphar.2021.684243

IF: 5.6

2021-06-29

Frontiers in Pharmacology

Abstract:Aberrant activation of the Ras–ERK signaling pathway drives many important cancer phenotypes, and several inhibitors targeting such pathways are under investigation and/or approved by the FDA as single- or multi-agent therapy for patients with melanoma and non–small-cell lung cancer (NSCLC). Here, we show that betulinic acid (BA), a natural pentacyclic triterpenoid, inhibits cell proliferation, and induces apoptosis and protective autophagy in NSCLC cells. Thus, the cancer cell killing activity of BA is enhanced by autophagy inhibition. Mitogen-activated protein kinases, and especially ERK that facilitates cancer cell survival, are also activated by BA treatment. As such, in the presence of ERK inhibitors (ERKi), lung cancer cells are much more sensitive to BA. However, the dual treatment of BA and ERKi results in increased protective autophagy and AKT phosphorylation. Accordingly, inhibition of AKT has a highly synergistic anticancer effect with co-treatment of BA and ERKi. Notably, autophagy inhibition by hydroxychloroquine (HCQ) increases the response of lung cancer cells to BA in combination with ERKi. In vivo , the three-drug combination (BA, ERKi, and HCQ), resulted in superior therapeutic efficacy than single or dual treatments in the xenograft mouse model. Thus, our study provides a combined therapy strategy that is a highly effective treatment for patients with NSCLC.

pharmacology & pharmacy
Pilot randomized, non‐inferiority, cross‐over trial of once‐weekly vs. three times‐weekly recombinant factor VIII prophylaxis in adults with severe haemophilia A

M. Ragni,Jonathan G. Yabes,P. F. Fogarty,Neil C. Josephson,C. M. Kessler,Anne T. Neff,Leslie Raffini,K. Brummel‐Ziedins,Charity G. Moore

DOI: https://doi.org/10.1111/hae.13131

2017-01-01

Haemophilia

Abstract:M. V. RAGNI,*† J . G. YABES,‡ P. F. FOGARTY,§ N. C. JOSEPHSON,¶ C. M. KESSLER,** A. T. NEFF,†† L. RAFFINI,‡‡ K. BRUMMEL-ZIEDINS§§ and C. G. MOORE‡ *Department of Medicine University of Pittsburgh Medical Center; †Hemophilia Center of Western Pennsylvania; ‡Center for Research on Health Care Data Center, University of Pittsburgh, Pittsburgh; §University of Pennsylvania, Philadelphia, PA; ¶Puget Sound Blood Center, Seattle, WA; **Georgetown University Medical Center, Washington, DC; ††Vanderbilt University Medical Center, Nashville, TN; ‡‡Children’s Hospital of Philadelphia, Philadelphia, PA; and §§Department of Biochemistry University of Vermont, Colchester, VT, USA

[Evaluation of the effects of a beta-blocking drug (moprolol) on hemodynamics and lesion potentials in acute myocardial infarct].

Bruceine D suppresses CAF-promoted TNBC metastasis under TNF-α stimulation by inhibiting Notch1-Jagged1/NF-κB(p65) signaling

Bruceine D Induces Apoptosis in Human Non-Small Cell Lung Cancer Cells Through Regulating JNK Pathway

Bruceine a exerts antitumor effect against colon cancer by accumulating ROS and suppressing PI3K/Akt pathway

Betulinic acid impairs metastasis and reduces immunosuppressive cells in breast cancer models

Unveiling the therapeutic potential: KBU2046 halts triple-negative breast cancer cell migration by constricting TGF-β1 activation in vitro

Bruceine B Displays Potent Antimyeloma Activity by Inducing the Degradation of the Transcription Factor C-Maf.

Proliferation, migration and invasion of triple negative breast cancer cells are suppressed by berbamine via the PI3K/Akt/MDM2/p53 and PI3K/Akt/mTOR signaling pathways

Bruceae Fructus Oil Inhibits Triple-Negative Breast Cancer by Restraining Autophagy: Dependence on the Gut Microbiota-Mediated Amino Acid Regulation

Bruceine D induces lung cancer cell apoptosis and autophagy via the ROS/MAPK signaling pathway in vitro and in vivo

Viable Aortic Valve Heterotransplantation

Betulinic Acid Suppresses Breast Cancer Metastasis by Targeting GRP78-Mediated Glycolysis and ER Stress Apoptotic Pathway

Betulinic acid in the treatment of breast cancer: Application and mechanism progress

Bruceine D and Narclasine inhibit the proliferation of breast cancer cells and the prediction of potential drug targets

Transdermal Delivery of Brucine-Encapsulated Liposomes Significantly Enhances Anti-Tumor Outcomes in Treating Triple-Negative Breast Cancer.

Betulinic acid inhibits stemness and EMT of pancreatic cancer cells via activation of AMPK signaling

Betulinic acid inhibits the proliferation of human laryngeal carcinoma cells through reactive oxygen species-mediate mitochondrial apoptotic pathway

Baicalein promotes KDM4E to induce BICD1 and inhibit triple‐negative breast cancer progression by blocking PAR1 signaling

3-Acetyl-11-keto-β-boswellic acid inhibits cancer cell invasion and induces apoptosis in breast cancer cells by abrogating the EGFR-mediated PI3K/Akt pathway

Combination Treatment With Inhibitors of ERK and Autophagy Enhances Antitumor Activity of Betulinic Acid in Non–small-Cell Lung Cancer In Vivo and In Vitro

Pilot randomized, non‐inferiority, cross‐over trial of once‐weekly vs. three times‐weekly recombinant factor VIII prophylaxis in adults with severe haemophilia A